About

Cleerly Health improves the diagnosis and treatment of heart disease using artificial intelligence to analyze coronary computed tomography angiography (CCTA) imaging. This technology helps clinicians detect atherosclerosis earlier and provides detailed insights into plaque types, allowing for personalized treatment plans. Unlike traditional methods, Cleerly's platform offers a more comprehensive evaluation of cardiovascular health. The goal is to enhance patient outcomes and financial results for healthcare providers through actionable clinical insights.

Simplify's Take

What believers are saying

• Cleerly raised $106M to scale growth and clinical evidence generation.
• AI-driven personalized treatment plans are gaining traction in healthcare.
• The FDA's Breakthrough Device Designation supports Cleerly's innovative technologies.

What critics are saying

• Increased competition from AI-driven cardiovascular imaging companies could impact market share.
• Rapid technological advancements require Cleerly to continuously innovate.
• Potential regulatory challenges may arise with expanding AI-based solutions.

What makes Cleerly unique

• Cleerly integrates AI with clinical science for coronary artery disease insights.
• Their platform transforms complex imaging data into actionable insights for personalized treatment.
• Cleerly's FDA-cleared solutions offer non-invasive coronary artery disease phenotyping.

Help us improve and share your feedback! Did you find this helpful?

YesNo